Know the
Target Audience
This event has many interactive sessions on Oncology, Hematology and Radiation Oncology
various diagnostic and therapeutic advancements which would focus on the recent trends in the
field and would pave way for more research in the field
- Oncologists
- Researchers
- Academicians
- Research Scholars
- Students
- Geneticists
- Nurse Practitioners
- Industrialists
- Radiologists
- Biologists
- Radiation oncologists
- Radiation physicists
- Dosimetrists
- Radiation therapists
- Medical oncologists
- Radiation oncology
- administrators
- Surgical Oncologists
- Radiation therapists
- Radiation oncology nurses
- Diagnostic radiologists
- All other health professionals involved in the field of Oncology, Hematology and Radiation
Oncology
Know the
Event Tracks
-
Breast cancers
-
Hematology
-
Palliative Care
-
Physics
-
CNS Cancers
-
Gynecological Cancers
-
Lung Cancers
-
GU Cancers
-
GI Cancers
-
Head & Neck Cancers
SCHEDULE DETAILS
Scientific Program ( Agenda )
07:00 AM – 08:00 AM
Registration
08:00 AM – 08:05 AM
Opening Remarks
Chair Persons: Abdullah Al Zahrani, Abdulsalam Al Najjar, Shawqi Bazarbashi, M Rahal.
GI Cancer Session
—
08:05 AM – 08:20 AM
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
Dr. Riechelmann Rachel
08:20 AM – 08:35 AM
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.
Dr. Mohamed Salem
08:35 AM – 08:50 AM
Pembrolizumab With or Without Chemotherapy Versus Chemotherapy in Advanced G/GEJ Adenocarcinoma: The Phase 3, KEYNOTE-062 Study
Dr. Hafez Halwani
8:50 AM – 11:00 AM
Opening Ceremony
11:00AM – 11:20 AM
Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Dr. Mohamed Salem
11:20 AM – 11:40 AM
APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Dr. Riechelmann Rachel
11:40 AM – 12:00 PM
Discussion
(12:00 PM – 01:00 PM)
Prayer and Lunch
Breast Cancer Session
—
Chair Persons: Ahmed Abdulwarith, Dahish Ajarim, Ahmed Alfaraj, Huda Abdulkareem.
01:00 PM – 01:20 PM
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
Dr. Ahmed Saadelddin
01:20 PM – 01:40 PM
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
Dr. Omalkhair
01:40 PM – 02:00 PM
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
Dr. Adhar Alsayed
02:00 PM – 02:20 PM
Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.
Dr, Meteb Alfoheidi
(02:20 PM – 02:35 AM)
Discussion
(02:35 PM – 02:45 PM)
Coffee Break
Lung Cancer Session
—
Chair Persons: Essam Murshid, Majed Alothman, Mohammed Al Qarni, Hadi Almutairi
02:45 PM – 03:05 PM
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
Dr. Hamed Alhussaini
03:05 PM – 03:25 PM
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
Dr. Khalid Alsaleh
03:25 PM – 03:45 PM
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).
Dr. Turki Alfaye
03:45 PM – 04:05 PM
ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
Dr. A Jazieyah
(04:05 PM – 04:20 PM)
Discussion
(04:20 PM – 04:30 PM)
Coffee Break
GU Cancer Session
—
Chair Persons: Amin Tijani, Abdullah Al Tuwairqi, Khalid Bawazeer, Mubarak Almansour.
04:30 PM – 04:50 PM
Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.
Dr. Abdalluh Alsharm
04:50 PM – 05:10 PM
First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Dr. Rola Mufti
05:10 PM – 05:30 PM
Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
Dr. Emad Tashkandi
05:30 PM – 05:50 PM
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Dr. Nedal Bukhari
(05:50 PM – 06:05 PM)
Discussion
Closing Remarks
(07:00 AM – 08:00 AM)
Registration
Hematology Updates Session
—
Chair Persons: Basem Bayroti, Ahmed Alsaeed, Mosa Al Zahrani, Ahmed Alsageir.
08:00 AM – 08:20 AM
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).
Dr. Solaf Khanfar
08:20 AM – 08:40 AM
A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Dr. Majed Alahmadi
08:40 AM – 09:00 AM
Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Dr. Turky Alwessaidi
09:00 AM – 09:20 AM
Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Dr. Ayman Hejazi
09:20 AM – 09:40 AM
Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities
Dr. Zayed Alzahrani
(09:40 AM – 10:05 AM)
Discussion
(10:05 AM – 10:15 AM)
Coffee Break
Sarcoma / Symptoms and Survivorship
—
Chair Persons: Sameer Futaih, Mohammed Alghamdi, Fayez Alruwaili, Hafez Ghanem
10:15 AM – 10:35 AM
ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
Dr. Ashwaq Alolayan
10:35 AM – 10:55 AM
STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.
Dr. Abdullah Alsuhail
10:55 AM – 11:15 AM
A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.
Dr. Abdullah Alsuhail
11:15 AM – 11:35 AM
Effects of exercise on cancer-related fatigue and muscular strength in patients with breast cancer.
Dr. Abdulaziz Aljuhani
(11:35 AM – 11:45 AM)
Discussion
(11:45 AM – 01:00 PM)
Prayer and Lunch
Breast Cancer/GYN Session
—
Chair Persons: Abdul Aziz Al Hamad, Abdurrahman Al Shehri, Tawfeeq Tawfeeq, Jameelah Azhari.
01:00 PM – 01:20 PM
Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.
Dr. Shmidt
01:20 PM – 01:40 PM
Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).
Dr. Shmidt
01:40 PM – 02:00 PM
Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Dr. Hafez Halwani
02:00 PM – 02:20 PM
A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.
Dr. Shady Khayat
(02:20 PM – 02:45 PM)
Discussion
(02:45 PM – 02:55 PM)
Coffee Break
CNS / Melanoma / Head and Neck Session
—
Chair Persons: Ahmed Alwabari, Ibraheem Madkhali, Majed Aljahel, Ahmed Badeeb.
02:55 PM – 03:15 PM
Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.
Dr. Marwan Alhujaili
03:15 PM – 03:35 PM
Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
Dr. Faisal Azam
03:35 PM – 03:55 PM
Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.
Dr. Ahmed Alshehri
03:55 PM – 04:15 PM
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Dr. Riyadh Dada
(04:15 PM – 04:40 PM)
Discussion
Closing Remarks
Physicians
SAR250
1000/1000
Non-Physicians and Students
SAR200
1000/1000
Sponsor
Why Sponsor With Us